FDA - Search News

FDA Approves 1st Non-Opioid Pain Medicine in 20 Years

CNN on MSN · 5h

FDA approves first new type of pain medication in 25 years

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Newsweek on MSN · 9h

What Is Journavx? First Pain Medication Approved by FDA in Over Two Decades

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

The Washington Post · 10h

FDA approves new, non-opioid painkiller Journavx

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

Ozempic receives FDA nod for treating chronic kidney disease

CNN on MSN · 2d

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

U.S. News & World Report · 1d

FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes

Doctors already use Ozempic to manage type 2 diabetes and reduce the risk of heart disease in patients with diabetes. This move, as reported by The Times, was based on research sh

Hosted on MSN · 1d

Ozempic receives FDA nod for treating chronic kidney disease; experts explain how diabetes drug reduces CKD risk

The US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug, showed a reduced risk of kidney failure. Experts explain how the drug helps.

Axsome, FDA and migraine

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

Business Insider · 13h

Axsome Therapeutics announces FDA approval of Symbravo

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in

Seeking Alpha on MSN · 12h

Axsome gets FDA approval for Symbravo for migraine

Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo, a combination of meloxicam and rizatriptan,

FDA upgrades recall of Lay's potato chips

Newsweek on MSN · 1d

Chocolate Recall Update As FDA Sets Highest Risk Level for 9 States

A recall which was issued across nine states has now been given the highest risk classification by the federal agency.

Fortune on MSN · 1d

FDA reclassifies Lay’s potato chips recall to the highest risk level, warning the chips could cause ‘serious adverse health consequences or death’

The FDA has raised the risk level on a recall of Lay’s potato chips to the highest level, warning the recalled product could cause death. The chips were originally recalled last month for containing undeclared milk.

USA Today · 1d

Lay's potato chips recall upgraded to FDA's most serious level. Is Ohio affected?

The FDA elevated Lay's Classic Potato Chips to the highest risk level. Here what to know, and whether the recall impacts Ohio.

14h

US FDA Identifies Cybersecurity Risks in Certain Patient Monitors

(Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks ...

13h

Walmart's Broccoli Recall Now Classified As Potentially Deadly, According To The FDA

In early January it was revealed that Walmart's washed and ready-to-eat 12 oz. Marketside Broccoli Florets were voluntarily ...

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results